Objective To investigate the clinical effect of rivaroxaban combined with folic acid in the treatment of live-doid vasculopathy(LV).Methods Totally 20 LV patients admitted to the Kaifeng People's Hospital from March 2022 to June 2023 were selected.All patients were given orally rivaroxaban 10 mg/d and folic acid tablets 5 mg/d.The skin lesion symptoms and pain degree,thromboelastogram index,vasculo-related factors,inflammatory factors and erythro-cyte folic acid levels before treatment,4 weeks and 8 weeks of treatment were compared.The adverse reactions and re-currence were observed during treatment.Results The scores of erythema,ulcer and pain in LV patients before treat-ment were(2.34±0.58),(2.41±0.54)and(7.86±1.68),which decreased to(1.53±0.46),(1.48±0.38)and(4.57±1.32)after 4 weeks of treatment.After 8 weeks of treatment,the results decreased to(1.05±0.71)points,(0.88±0.28)points and(0.75±0.53)points,and the differences were statistically significant at different time points(P＜0.05).The R values and K values of LV patients before treatment were(4.97±1.44)and(1.95±0.21),which increased to(7.18±1.52)and(2.36±0.18)after4 weeks of treatment,and increased to(7.37±1.28)and(2.49±0.27)after 8 weeks of treatment.After 4 weeks of treatment and 8 weeks of treatment,the difference was statistically signifi-cant(P＜0.05).The levels of vascular endothelial growth factor and nitric oxide in LV patients were(947.66±237.84)ng/L and(44.96±8.47)μmol/L before treatment,and increased to(1 636.54±295.85)ng/L and(65.72±9.71)µmol/L after 4 weeks of treatment.After 8 weeks of treatment,the levels increased to(2374.95±363.78)ng/L and(83.75±10.82)μmol/L.The levels of soluble vascular endothelial growth factor receptor-1 and endothelin-1 were(12 626.95±595.06)ng/L and(105.72±9.74)ng/L before treatment,and decreased to(9 874.58±527.92)ng/L and(71.63±10.35)ng/L after4 weeks of treatment.After 8 weeks of treatment,the lev-els decreased to(8 479.60±462.84)ng/L and(52.86±8.72)ng/L,and the differences were statistically significant at different time points(P＜0.05).The levels of interleukin-6 and C-reactive protein in LV patients were(82.83±5.94)and ng/L(42.86±5.92)mg/L before treatment,and decreased to(56.92±6.69)ng/L and(27.83±7.28)mg/L after 4 weeks of treatment.After 8 weeks of treatment,the levels decreased to(32.55±4.96)ng/L and(11.74±4.28)mg/L,and the differences were statistically significant at different time points(P＜0.05).The eryth-rocyte folate level in LV patients was(426.92±37.82)mg/L before treatment,increased to(615.25±43.37)mg/L after 4 weeks of treatment,and increased to(773.72±46.82)mg/L after 8 weeks of treatment,with statistical signifi-cance at different time points(P＜0.05).Conclusion Rivaroxaban combined with folic acid in the treatment of LV can effectively improve the symptoms of blood damage and relieve pain,and its mechanism may be related to improving coag-ulation function,inhibiting inflammatory response and increasing the level of folic acid in red blood cells.
RivaroxabanFolic acidLivedoid vasculopathyCoagulation function
NETL
NSTL
万方数据
